ArticleFrontiers in medicine2026
A clinical investigation using reflectance confocal microscopy to evaluate the add-on efficacy of the Shumin treatment instrument combined with doxycycline for rosacea.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to compare the clinical efficacy and safety of two rosacea treatment regimens: oral doxycycline plus the Shumin treatment instrument and oral doxycycline plus red light therapy. Objective assessments, including reflectance confocal microscopy, were used to evaluate both regimens. Materials and methods: A total of 60 patients with rosacea were randomly divided into two groups, each containing 30 patients. The control group received doxycycline (100 mg/day) orally combined with red light therapy for 12 weeks (twice a week), whereas the experimental group received doxycycline (100 mg/day) orally combined with Shumin treatment instrument therapy for 12 weeks (twice a week). Results: The efficacy rate was 93.3% in the experimental group and 80.0% in the control group. Following treatment, significant reductions in Dermatology Life Quality Index scores and Demodex counts were achieved in both groups (all Conclusion: When used as an adjunctive therapy with oral doxycycline, the Shumin device yields better clinical outcomes than red light therapy for treating rosacea and has a favorable safety profile. These preliminary results establish a basis for the use of adjuvant physical interventions for rosacea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.